The relevance of PCSK9 as a new molecular target for treating hypercholesterolemia and associated cardiovascular diseases is demonstrated by the clinical efficacy of two FDA/EMA-approved monoclonal antibodies: alirocumab and evolocumab [5]. This evidence concerns the gene PCSK9 and familial hypercholesterolemia.